EUDA (39) BMGL (58) PIII (38) DCGO (43) ⌘ Pro Terminal →

ALPS Group Inc Ordinary Share (ALPS) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell ALPS stock right now?

ALPS Group Inc Ordinary Share (ALPS) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

Q: What is ALPS's 12-month price target and RQD AI Jury consensus?

ALPS's 12-month base price target is $0.32 (range $0.25 to $1.84), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.32 -0.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.32

ALPS Group Inc Ordinary Share (ALPS) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $54.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.32 (-0.20%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALPS)Realized 20D OHLCV Swing Band: ±10.2%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY ALPS SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (23% of score)

20D Institutional Volume Accumulation (±10.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$0.37-8.1% Next Q

Q2 (-2Q)

Grade C+$0.34-2.9% Next Q

Q3 (-1Q)

Grade C$0.33-3% Next Q

Current

Grade D+$0.32-0.2% Hist 90D α

Trajectory: C+ (65) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALPS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, ALPS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.37) or 200D SMA ($0.68) invalidates the momentum regime and cuts Target Base ($0.32) toward Bear Floor ($0.25).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALPS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALPS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

27.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE6% OF RANGE

L: $0$0.32H: $2

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ALPS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

22/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like ALPS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALPS)

✓Walkthrough of ALPS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALPS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.44%▼ SUPPORT BREAKDOWN

2026-10-30O $0.32H $0.33L $0.32C $0.32VOL 36.2K

RES: $0.39SUP: $0.32SMA50: $0.37SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALPS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALPS Butterfly Map → + Track ALPS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALPS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALPS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALPS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALPS)

Health Care Rank #258 of 1016 ⚔️ EUDA vs ALPS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALPS vs. EUDA, BMGL, PIII, DCGO)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ALPS Group Inc Ordinary Share (ALPS) ranks #258 by composite RQD confidence (57/100, grade D+) and #739 by equity capitalization ($54.1M). Within this direct 5-issuer industry benchmark cohort, ALPS leads on earnings valuation at N/A trailing P/E, while EUDA leads on capital efficiency and profitability with -35.0% ROIC and 43.9% gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ALPS at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALPS ACTIVE ALPS Group Inc Ordinary Share	D+	57/100	—	—	—	-0.03%	$54.1M	Benchmark Subject
EUDA EUDA Health Holdings Limited	D-	39/100	—	43.9%	-35.0%	+1.31%	$46.4M	/euda-vs-alps →
BMGL Basel Medical Group Ltd	D+	58/100	—	—	—	+3.26%	$36.0M	/bmgl-vs-alps →
PIII P3 Health Partners Inc. (Class A)	D-	38/100	—	—	-35.0%	+4.22%	$30.5M	/piii-vs-alps →
DCGO DocGo Inc.	D-	43/100	—	—	-35.0%	-2.43%	$27.0M	/dcgo-vs-alps →

2. ALPS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

ALPS Group Inc Ordinary Share (ALPS) operates in Medical/Nursing Services (Health Care) with an equity capitalization of $54.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ALPS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ALPS Group Inc Ordinary Share (NASDAQ: ALPS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $0.32 (-0.03% 1D, market cap $54.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ALPS ranks #258 in composite RQD confidence.

How does ALPS compare to EUDA and BMGL in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), ALPS carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EUDA (EUDA Health Holdings Limited) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, ALPS leads on earnings multiple (N/A) while EUDA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALPS?

For ALPS Group Inc Ordinary Share (ALPS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #258 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALPS trading relative to its 50-day, 200-day, and 52-week technical levels?

ALPS last traded at $0.32 (-0.03% on volume of 28,769 shares), positioning the stock -13.51% below its 50-day simple moving average ($0.37) and -52.94% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.23 to $1.75, ALPS sits at the 5.9% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±10.2% ($1.00 to $0.35).

ALPS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALPS stock right now?

ALPS Group Inc Ordinary Share (ALPS) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is ALPS's 12-month price target and RQD AI Jury consensus?

ALPS's 12-month base price target is $0.32 (range $0.25 to $1.84), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALPS RQD Cockpit ALPS 12M Forecast ALPS Earnings & Move ALPS Dividends & DRIP ALPS Insiders & 13F ALPS Whale Options ALPS Profit Sankey ALPS News & Why